These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17540689)

  • 1. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.
    Daly CA; Hildebrandt P; Bertrand M; Ferrari R; Remme W; Simoons M; Fox KM;
    Heart; 2007 Nov; 93(11):1406-11. PubMed ID: 17540689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.
    Battes L; Barendse R; Steyerberg EW; Simoons ML; Deckers JW; Nieboer D; Bertrand M; Ferrari R; Remme WJ; Fox K; Takkenberg JJ; Boersma E; Kardys I
    Am J Cardiol; 2013 Jul; 112(1):27-33. PubMed ID: 23558041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.
    Aguilar D; Fisher MR; O'Connor CM; Dunne MW; Muhlestein JB; Yao L; Gupta S; Benner RJ; Cook TD; Edwards D; Pfeffer MA;
    Am Heart J; 2006 Aug; 152(2):298-304. PubMed ID: 16875914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
    Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease.
    Hu R; Ma CS; Nie SP; Lü Q; Kang JP; Du X; Zhang Y; Gao YC; He LQ; Jia CQ; Liu XM; Dong JZ; Liu XH; Chen F; Zhou YJ; Lü SZ; Wu XS
    Chin Med J (Engl); 2006 Nov; 119(22):1871-6. PubMed ID: 17134585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2).
    Cheung BM; Wat NM; Man YB; Tam S; Cheng CH; Leung GM; Woo J; Janus ED; Lau CP; Lam TH; Lam KS
    Am J Hypertens; 2008 Jan; 21(1):17-22. PubMed ID: 18091739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
    Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3.
    Gupta R; Sarna M; Thanvi J; Rastogi P; Kaul V; Gupta VP
    Indian Heart J; 2004; 56(6):646-52. PubMed ID: 15751521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity paradox in patients with hypertension and coronary artery disease.
    Uretsky S; Messerli FH; Bangalore S; Champion A; Cooper-Dehoff RM; Zhou Q; Pepine CJ
    Am J Med; 2007 Oct; 120(10):863-70. PubMed ID: 17904457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
    Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
    de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE;
    Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
    Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
    Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
    Norhammar A; Malmberg K; Diderholm E; Lagerqvist B; Lindahl B; Rydén L; Wallentin L
    J Am Coll Cardiol; 2004 Feb; 43(4):585-91. PubMed ID: 14975468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Admission with metabolic disorder is a useful predictor of the 1-year prognosis for patients with unstable angina, but not for patients with acute myocardial infarction: east-Osaka acute coronary syndrome registry.
    Hoshida S; Teragaki M; Lim YJ; Mishima M; Nakajima O; Kijima Y; Yoshimaru K; Tsuchihashi M; Morita Y; Iwasaka T;
    Coron Artery Dis; 2011; 22(6):416-20. PubMed ID: 21555939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.